ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Tools for ADC PK Analysis——Anti-payload antibodies

Tools for ADC PK Analysis——Anti-payload antibodies

Tools for ADC PK Analysis——Anti-payload antibodies
Product Features
High Purity (>90%)
High affinity and specificity validated
High sensitivity verified by ADCs binding assay
Complete technical support solution
Click here to view data >>
Research Applications
ELISA PK/PD studies on ADCs in preclinical and clinical
DAR value detection
Background
Characterizing biological drugs is a critical step throughout the drug development process, starting from development to clinical evaluation.
Antibody-drug conjugates (ADCs) have a complex and varied structure. With the addition of matrix complexity and species, DAR and PK/PD studies need to be comprehensively evaluated for each component. Each of ADC's component having different gold standards for characterization. This includes utilizing analytical methods such as ELISAs and LC-MS.
Type Analyte Detail Typical Method
Total Antibody Conjugated, partially unconjugated, and fully unconjugated (DAR > 0) Ligand Binding Assay
Conjugated Antibody Antibody with minimum DAR > 1 Ligand Binding Assay
Antibody-conjugated Drug Total small-molecule drug conjugated to Antibody Affinity LC-MS / Ligand Binding Assay
Unconjugated Drug Small molecule drug not conjugated to antibody LC-MS
Total Drug Total unconjugated and conjugated Drug LC-MS

ADC molecule type and typical analytical methods for evaluation. 1

Different LBA formats to analyze ADCs in serum

Different LBA formats to analyze ADCs in serum 2

To assist with your PK studies when evaluating your ADCs, ACROBiosystems now offer several anti-payload antibodies with a high affinity that bind specifically to DM-1, DXD, SN38, MMAE, and more! Don’t forget, we also offer HRP-conjugated anti-MMAE antibodies to eliminate the need for a secondary antibody!
Product List
Molecule Cat. No. Product Description Preorder/Order
Great news! More high-quality anti-payload antibodies are coming soon from ACROBiosystems. If you have any suggestions or custom requirements, please click here to contact us.

Supplemental Data
High purity verified by SEC-MALS
High purity verified by SEC-MALS

The purity of Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.

High affinity binding to MMAE-ADC validated
High affinity binding to MMAE-ADC validated

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

High affinity binding to MMAE-ADC validated

Immobilized Disitamab Vedotin at 1 μg/mL (100 μL/well) can bind HRP conjugated Anti-MMAE Antibody, mAb (Cat. No. MME-PLS104) with a linear range of 0.5-16 ng/mL (QC tested).

High affinity binding to PTX-ADC validated
High affinity binding to PTX-ADC validated

Immobilized ADC-PTX at 1 μg/mL (100 μL/well) can bind Mouse Anti-PTX Antibody, Mouse IgG2a (MALS verified) (Cat. No. PTX-S343) with a linear range of 0.106-6.767 ng/mL (QC tested).

High affinity binding to SN38- ADC validated
High affinity binding to MMAE-ADC validated

Immobilized ADC-SN38 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SN38 Antibody (Cat. No. SN8-S223) with a linear range of 0.05-1.56 ng/mL (QC tested)

Related Products

The key reagents to the evaluation of ADC immunogenicity - Anti-idiotypic antibodies
Molecule Cat. No. Product Description Neutralizing activity Application
Adalimu*ab ADB-Y19 Anti-Adalimu*ab Antibodies (AY19) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Adalimu*ab ADB-Y23b Anti-Adalimu*ab Antibodies (AY23b) (recommended for PK/PD) Non-Neutralizing Antibody PK bridging ELISA; Indirect ELISA
Bevacizu*ab BEB-Y10 Anti-Bevacizu*ab Antibodies (AY10) (MALS verified, recommended for PK/PD) Neutralizing Antibody PK bridging ELISA; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-Y12 Anti-Bevacizu*ab Antibodies (AY12) (recommended for neutralizing assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-Y9 Anti-Bevacizu*ab Antibodies (AY9) (recommended for ADA assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-BY13 Biotinylated Anti-Bevacizu*ab Antibodies (AY13) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA;Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-Y27 Anti-Cetuxi*ab Antibodies (AY27) (recommended for ADA assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-Y31 Anti-Cetuxi*ab Antibodies (AY31) (Non-Neutralizing) Non-Neutralizing Antibody ADA assay; Indirect ELISA
Cetuxi*ab CEB-Y28 Anti-Cetuxi*ab Antibodies (AY28) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-BY31 Biotinylated Anti-Cetuxi*ab Antibodies (AY31) (recommended for PK/PD) Non-Neutralizing Antibody PK bridging ELISA; Indirect ELISA
Rituxi*ab RIB-Y36 Anti-Rituxi*ab Antibodies (AY36) (recommended for ADA assay) Neutralizing Antibody ADA assay;Neutralizing assay; Indirect ELISA
Rituxi*ab RIB-Y37 Anti-Rituxi*ab Antibodies (AY37) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA;Neutralizing assay;Indirect ELISA
Rituxi*ab RIB-Y35c Anti-Rituxi*ab Antibodies (MALS verified) Non-Neutralizing Antibody ADA assay; Indirect ELISA
Trastuzu*ab TRB-Y5b Anti-Trastuzu*ab Antibodies (AY5b) (recommended for PK/PD) Non-Neutralizing Antibody Neutralizing Antibody
Trastuzu*ab TRB-Y1b Anti-Trastuzu*ab Antibodies (AY1b) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA; Neutralizing assay; Indirect ELISA

>> Click to learn more core reagents accelerating ADC’s development!
Antibody-Drug Conjugates (ADCs): the Magic Bullets for Treatment

References

1. Gorovits, B. et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5, 997–1006 (2013).

2. Qin, Q. & Gong, L. Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices. Molecules 27, 1–17 (2022).

ACRO Quality

This web search service is supported by Google Inc.

totopphone